Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Diprophylline→

Diprophylline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
479-18-5
Molecular formula
C10H14N4O4
Molecular weight
254.24 g/mol
Drug class
Methylxanthine bronchodilatortheophylline derivative
Mechanism of action
Produces bronchodilation through methylxanthine pharmacology, including phosphodiesterase inhibition and adenosine-receptor antagonism, increasing intracellular cyclic AMP in bronchial smooth muscle. Clinical effect and adverse effects depend on systemic exposure.
Indications / reported uses
  • Historically used for symptomatic treatment of asthma and bronchospasm in countries where diprophylline products remain authorised; current role is limited by availability and the narrow therapeutic margin of methylxanthines

Sources: NLM MeSH — Diprophylline · PubMed — Diprophylline methylxanthine bronchodilator · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Diprophylline Environmental Risk Assessment (ERA) (the Diprophylline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.